Our vision

No dog will be born into a laboratory cage.

We are ending the commercial breeding of dogs for laboratory testing in the United States. Not eventually. Not someday. In the next several years. Here is why that outcome is no longer in doubt.

The argument

It has already happened. Twice.

When you say a thing is going to happen, the first question is whether anyone has done it before. The largest commercial dog breeders for laboratories in the United States have been closed twice in the last four years.

In 2022, the Department of Justice closed Envigo’s Cumberland, Virginia facility under the Animal Welfare Act. 4,000 beagles were freed in six weeks through a partner network of more than 120 rescue groups. The parent company paid the largest AWA penalty in U.S. history.

In 2026, after a 10-year campaign of investigation, legal pressure, federal leadership, and direct citizen action, Ridglan Farms agreed to release 1,500 of the 2,000 beagles in its Wisconsin facility to accredited rescue. The breeding license expires in July 2026.

The third closure is Marshall BioResources. The mechanism is built. The coalition is broad. The political math is settled. The only remaining variable is how long the company tries to stretch out what is already a foregone conclusion.

Why this is inevitable

Five forces. None reversible.

  1. 01

    The federal mechanism exists, and it has been used.

    The U.S. Department of Justice can sue commercial dog breeders under the Animal Welfare Act. It has done so. The largest penalty in AWA history has already been imposed. There is nothing about Marshall’s legal status that distinguishes it from Envigo or Ridglan.

  2. 02

    Federal Republicans and Democrats agree on this.

    Rep. Mark Pocan (D-WI 2) and Rep. Nancy Mace (R-SC) are both on the public record. Conservative voices including Lara Trump, Laura Loomer, and Tomi Lahren have spoken against the practice. This is one of the few questions in American politics where the political coalition is not in dispute.

  3. 03

    The conditions are documented, and they are not defensible.

    Federal inspectors do not require activists to identify violations. Ridglan accumulated 311. Envigo’s record included puppies dead from cold exposure, food contaminated with maggots, and dogs killed instead of treated. The next inspection report will read like the last two.

  4. 04

    Rescue infrastructure is built and trained.

    More than 120 rescue groups successfully placed 4,000 beagles in six weeks. The same network is ready for Marshall. There is no scenario in which the dogs cannot be moved.

  5. 05

    Public opinion is settled.

    Beagles bred for vivisection. Vocal cords cut without anesthesia. Surgery on conscious dogs. Once the public sees the conditions, the question is no longer political. The Ridglan campaign demonstrated that visibility is sufficient.

What victory looks like

The end of the supply chain.

Closing one facility, even Marshall, is not the end. It is the demonstration. Once the United States no longer has a commercial-scale supply of beagles bred for laboratories, the laboratories will pivot.

They will pivot toward the alternatives that already exist: organ-on-chip technology, computational toxicology, in-vitro testing, validated cell-based assays. These methods are already in widespread use. They are already faster, cheaper, and more accurate predictors of human response than dog studies. The reason laboratories still buy beagles is institutional inertia — not science.

Ending the breeding ends the inertia. That is the strategic shape of this campaign. It is not "stop one bad facility." It is "remove the input that the laboratory dog studies depend on, and let the system reorganize around methods that work better and do not require torturing animals."

The closing

This is possible.
It is, in fact, inevitable.

We are not asking anyone to imagine an outcome that has never been observed. We are pointing at one that has been observed twice and will be observed again. The work between now and the closure of Marshall BioResources is not strategic uncertainty. It is logistics.